Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127087 · ClinicalTrials.gov registry record · Phase 1
Oxazyme in Patients With Hyperoxaluria
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01127087: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01127087 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01127087, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be increased. Both effects would decrease blood levels of oxalate, and hence oxalate excretion in the urine.
Interventions
- DRUG Oxazyme
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127087
The ClinicalTrials.gov registry entry for NCT01127087 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxazyme is the first listed.
NCT01127087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127087 about?
NCT01127087 is a clinical study titled "Oxazyme in Patients With Hyperoxaluria". Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intest...
What is the current status of trial NCT01127087?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01127087?
The interventions under investigation include: Oxazyme (DRUG).
Who is sponsoring clinical trial NCT01127087?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.